## Steroid-Sparing Strategy in Responding PV **Key Point:** Once clinical response is evident (80% healing, no new lesions), the goal shifts from disease control to **minimizing cumulative corticosteroid exposure** by introducing steroid-sparing agents while tapering prednisolone. ### Timeline of PV Management ```mermaid flowchart TD A[Active PV diagnosed]:::outcome --> B[Start prednisolone 1 mg/kg/day]:::action B --> C[Assess response at 2-4 weeks]:::decision C -->|Good response| D[Introduce steroid-sparing agent]:::action C -->|Poor response| E[Increase dose or add second agent]:::action D --> F[Slow taper of prednisolone]:::action F --> G[Maintenance on steroid-sparing agent]:::action ``` ### Rationale for Azathioprine Addition **High-Yield:** Azathioprine is the **gold-standard steroid-sparing agent** for pemphigus vulgaris: - Onset: 4–8 weeks (allows prednisolone taper during this window) - Mechanism: Purine antagonist → T-cell suppression - Allows 50–75% reduction in prednisolone dose - Reduces relapse rate and cumulative steroid toxicity ### Dosing and Monitoring | Parameter | Detail | |-----------|--------| | **Azathioprine dose** | 1–2 mg/kg/day (typically 50–100 mg daily) | | **Baseline tests** | CBC, LFT, TPMT activity (if available) | | **Monitoring** | CBC, LFT every 2–4 weeks for first 3 months, then monthly | | **Prednisolone taper** | Reduce by 5–10 mg every 2–4 weeks once AZA is established | | **Target maintenance** | Prednisolone 0.5 mg/kg/day or lower on AZA | **Clinical Pearl:** The combination of prednisolone + azathioprine allows **faster tapering** and **lower cumulative steroid dose** than prednisolone monotherapy, reducing risk of opportunistic infections, osteoporosis, and metabolic complications. **Mnemonic:** **TAPS** — Timing (add steroid-sparer at response), Azathioprine (first-line), Prednisolone (taper), Steroid-sparing (goal). ### Why This Patient Needs Intervention NOW - 80% healing = **excellent response**, not a reason to escalate - Steroid side effects are **cumulative and dose-dependent** - Continuing high-dose prednisolone risks: hyperglycemia → diabetes, osteoporosis, infections, psychiatric complications - Azathioprine onset (4–8 weeks) means **early introduction** allows prednisolone reduction before side effects worsen [cite:Fitzpatrick's Dermatology 10e Ch 30; KD Tripathi 8e Ch 12] 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.